Birmingham, AL, February 12th 2020 – Vulcan Biosciences, Inc. announced today the hiring of Omar Flores, Ph.D., M.B.A., as Chief Executive Officer.  Dr. Flores has prior experience taking early stage pharmaceuticals into and through clinical trials as well as in venture capital.  His role at Vulcan Biosciences will be to oversee the financing and development of the company’s lead drug candidates for multiple sclerosis.  According to Archie Cobbs, Ph.D, Board Member of Vulcan Biosciences, “This critical leadership appointment will further advance Vulcan Biosciences’ mission to accelerate the development of breakthrough therapies for patients with multiple sclerosis. Our strategy for success is to put the best possible people and resources to work towards our goal, and Omar certainly fits that bill.”

Birmingham, AL, April 17th 2019 – The U.S. Food and Drug Administration (FDA) has chosen to partner with Vulcan Biosciences Inc. (formerly Vulcan Analytical) for cutting-edge blood protein research in sickle cell disease.  The critical findings from this research were published in the prestigious Journal of Clinical Investigation Insight and highlighted on the FDA website (see below).  Several new findings for sickle cell disease described in the paper were identified with Vulcan Biosciences software platform, PROTALIZER™, including the first evidence of ubiquitinylation of hemoglobin in sickle cell disease.  The study was conducting in the laboratory of Dr. Abdu Alayash, a Lab Chief in the Center for Biologics Evaluation and Research in collaboration with Dr. Michael Heaven, Chief Scientific Officer of Vulcan Biosciences. According to Dr. Heaven, “We’ve forged a great research partnership with the FDA. They were quick to recognize the power of our platform for making new discoveries, and this important research success is the result.”



Birmingham, AL, December 9th 2019 – The results obtained from an unbiased and thorough analysis of potential drug targets in multiple sclerosis has been successful, culminating in the identification of two new multiple sclerosis drug candidates: VBI-101, a small-molecule drug, and VBI-106, a protein biologic drug.  The Chief Scientific Officer of Vulcan Biosciences, Dr. Michael Heaven, stated “Both of the lead drug candidates found suppress paralysis symptoms in the in vivo mouse model of multiple sclerosis, have unique mechanisms of action, and show no signs of toxicity.”  Both drug candidates were found using the company’s own PROTALIZER™ mass spectrometry proteomics discovery platform.  The company plans to develop VBI-101 and VBI-106 further in additional preclinical studies, with the goal of filing an investigational new drug (IND) with the FDA in anticipation of further human clinical trials.

Birmingham, AL, August 1st 2019 – Vulcan Biosciences, Inc. a biotechnology company focused on finding more effective treatments for patients with multiple sclerosis, announced today that it has secured an undisclosed amount in a seed funding round from Birmingham area angel investors.  The funds raised will be utilized in a drug discovery program whose sole purpose is to identify better treatments for patients with multiple sclerosis, the most common autoimmune disease of the central nervous system.